Search company, investor...

Predict your next investment

Gilead Sciences company logo
Corporation
HEALTHCARE | Biotechnology
gilead.com

Investments

34

Portfolio Exits

10

Partners & Customers

10

Service Providers

3

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops, manufactures, and commercializes therapies for viral diseases, infectious diseases, and cancer utilized proprietary "combinatorial chemistry" technology to discover lead therapeutic and diagnostic compounds. Its primary areas of focus include HIV/AIDS, liver disease, and serious cardiovascular and respiratory conditions. The company was founded in 1987 and is based in Foster City, California.

Headquarters Location

333 Lakeside Drive

Foster City, California, 94404,

United States

650-574-3000

Want to inform investors similar to Gilead Sciences about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Expert Collections containing Gilead Sciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Gilead Sciences in 2 Expert Collections, including Fortune 500 Investor list.

F

Fortune 500 Investor list

590 items

This is a collection of investors named in the 2019 Fortune 500 list of companies. All CB Insights profiles for active investment arms of a Fortune 500 company are included.

D

Diabetes

1,904 items

Latest Gilead Sciences News

Gilead Acquires XinThera to Boost Oncology and Inflammation Pipeline

May 25, 2023

May 25, 2023 Gilead Sciences, Inc. announced on May 12, 2023, that it has acquired all outstanding shares of XinThera, a San Diego-based private biotech company. The acquisition will complement Gilead's existing clinical development priorities by adding pipeline assets for well-validated targets in oncology and inflammation. The research resources of XinThera have the potential to target the DNA damage repair pathway in the treatment of cancer and to control the immune response in the treatment of inflammatory diseases, which may lead to better outcomes for patients with these diseases. Become a Subscriber According to Flavius Martin, M.D., executive vice president of research at Gilead Sciences, the XinThera team has created best-in-class small molecule drugs for the treatment of cancer and immunologic conditions. Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved medical breakthroughs for over three decades, with the aim of making the world healthier for everyone. The acquisition of XinThera is a strategic move to strengthen Gilead's early pipeline in oncology and inflammation, two areas where the company already has a strong presence. Oncology is a major area of focus for Gilead Sciences, with several oncology products already on the market. The company's current oncology portfolio includes Yescarta, a CAR T-cell therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Trodelvy, a treatment for metastatic triple-negative breast cancer; and Zydelig, a treatment for certain types of blood cancers. Inflammation is another therapeutic area where Gilead Sciences has established itself as a leader. The company's current portfolio includes filgotinib, a JAK inhibitor for the treatment of rheumatoid arthritis, and selonsertib, an investigational therapy for the treatment of liver fibrosis. The acquisition of XinThera will add to Gilead's existing pipeline in oncology and inflammation, providing the company with additional promising compounds for the treatment of these diseases. This will enable Gilead to continue to deliver on its commitment to developing breakthrough therapies for patients in need. Gilead Sciences' acquisition of XinThera is a strategic move to strengthen its early pipeline in oncology and inflammation. The addition of XinThera's pipeline assets will complement Gilead's existing clinical development priorities and provide the company with additional promising compounds for the treatment of cancer and inflammatory diseases. With a strong track record of breakthroughs in medicine, Gilead Sciences is well-positioned to continue delivering innovative therapies that make a meaningful difference in the lives of patients.

Gilead Sciences Investments

34 Investments

Gilead Sciences has made 34 investments. Their latest investment was in Ensoma as part of their Series B - II on May 5, 2023.

CBI Logo

Gilead Sciences Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

5/16/2023

Series B - II

Ensoma

$50M

Yes

9

5/23/2022

Seed VC

Exavir Therapeutics

$4M

Yes

1

5/5/2022

Series B

Curebase

$40M

Yes

1

1/26/2022

Series B

Subscribe to see more

$99M

Subscribe to see more

10

12/27/2021

PIPE

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/16/2023

5/23/2022

5/5/2022

1/26/2022

12/27/2021

Round

Series B - II

Seed VC

Series B

Series B

PIPE

Company

Ensoma

Exavir Therapeutics

Curebase

Subscribe to see more

Subscribe to see more

Amount

$50M

$4M

$40M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

9

1

1

10

10

Gilead Sciences Portfolio Exits

10 Portfolio Exits

Gilead Sciences has 10 portfolio exits. Their latest portfolio exit was Tmunity on December 20, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/20/2022

Acquired

$99M

17

4/30/2021

IPO

$99M

Public

9

4/14/2021

Acq - Pending

$99M

2

7/30/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

7/24/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/20/2022

4/30/2021

4/14/2021

7/30/2020

7/24/2020

Exit

Acquired

IPO

Acq - Pending

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

17

9

2

10

10

Gilead Sciences Acquisitions

24 Acquisitions

Gilead Sciences acquired 24 companies. Their latest acquisition was XinThera on May 09, 2023.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

5/9/2023

Series B

$99M

$80M

Acquired

1

8/4/2022

Series B

$99M

$130.28M

Acquired

8

12/10/2020

Series B

$99M

$10.71M

Acquired

6

10/23/2020

Other Venture Capital

Subscribe to see more

$99M

$99M

Subscribe to see more

10

3/2/2020

Grant

Subscribe to see more

$99M

$99M

Subscribe to see more

10

Date

5/9/2023

8/4/2022

12/10/2020

10/23/2020

3/2/2020

Investment Stage

Series B

Series B

Series B

Other Venture Capital

Grant

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$80M

$130.28M

$10.71M

$99M

$99M

Note

Acquired

Acquired

Acquired

Subscribe to see more

Subscribe to see more

Sources

1

8

6

10

10

Gilead Sciences Partners & Customers

10 Partners and customers

Gilead Sciences has 10 strategic partners and customers. Gilead Sciences recently partnered with Roche on May 5, 2023.

Date

Type

Business Partner

Country

News Snippet

Sources

5/11/2023

Licensee

Switzerland

HOOKIPA Pharma Reports First Quarter 2023 Financial Results and Recent Business Highlights

The primary drivers of the increase in research and development expenses by $ 4.3 million compared to the three months ended March 31 , 2022 were higher clinical study expenses for our HB-200 program and higher expenses for research and development services for our HB-200 program , as well as increased spending for our Gilead and Roche partnered programs , partially offset by lower manufacturing expenses for our HB-200 and Gilead partnered programs .

2

5/9/2023

Licensor

United States

HOOKIPA Announces First Person Dosed in Phase 1a/b Clinical Trial of HB-400, in Collaboration with Gilead, for Treatment of Hepatitis B

NEW YORK and VIENNA , Austria , May 09 , 2023 -- HOOKIPA Pharma Inc. , a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform , today announced that the first person has been dosed in a Gilead-led Phase 1 clinical trial of HB-400 , an investigational therapeutic vaccine for chronic hepatitis B. HB-400 is one of two novel compounds being developed in collaboration with Gilead .

2

2/2/2023

Partner

United States

Gilead Sciences Announces Fourth Quarter and Full Year 2022 Financial Results

The increase was primarily driven by two charges in the fourth quarter of 2021 which did not recur in 2022 : the $ 1.25 billion charge for a legal settlement and the $ 625 million charge for the Arcus Biosciences , Inc. collaboration opt-in .

2

1/31/2023

Partner

United States

Subscribe to see more

Subscribe to see more

10

1/30/2023

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

5/11/2023

5/9/2023

2/2/2023

1/31/2023

1/30/2023

Type

Licensee

Licensor

Partner

Partner

Partner

Business Partner

Country

Switzerland

United States

United States

United States

United States

News Snippet

HOOKIPA Pharma Reports First Quarter 2023 Financial Results and Recent Business Highlights

The primary drivers of the increase in research and development expenses by $ 4.3 million compared to the three months ended March 31 , 2022 were higher clinical study expenses for our HB-200 program and higher expenses for research and development services for our HB-200 program , as well as increased spending for our Gilead and Roche partnered programs , partially offset by lower manufacturing expenses for our HB-200 and Gilead partnered programs .

HOOKIPA Announces First Person Dosed in Phase 1a/b Clinical Trial of HB-400, in Collaboration with Gilead, for Treatment of Hepatitis B

NEW YORK and VIENNA , Austria , May 09 , 2023 -- HOOKIPA Pharma Inc. , a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform , today announced that the first person has been dosed in a Gilead-led Phase 1 clinical trial of HB-400 , an investigational therapeutic vaccine for chronic hepatitis B. HB-400 is one of two novel compounds being developed in collaboration with Gilead .

Gilead Sciences Announces Fourth Quarter and Full Year 2022 Financial Results

The increase was primarily driven by two charges in the fourth quarter of 2021 which did not recur in 2022 : the $ 1.25 billion charge for a legal settlement and the $ 625 million charge for the Arcus Biosciences , Inc. collaboration opt-in .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

2

2

10

10

Gilead Sciences Service Providers

7 Service Providers

Gilead Sciences has 7 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Acq - P2P, and Acquired

Investment Bank

Financial Advisor

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Subscribe to see more

Associated Rounds

Acq - P2P, and Acquired

Subscribe to see more

Subscribe to see more

Provider Type

Investment Bank

Subscribe to see more

Subscribe to see more

Service Type

Financial Advisor

Subscribe to see more

Subscribe to see more

Partnership data by VentureSource

Gilead Sciences Team

35 Team Members

Gilead Sciences has 35 team members, including current Chief Executive Officer, Michael Riordan.

Name

Work History

Title

Status

Michael Riordan

Chief Executive Officer

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Michael Riordan

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Chief Executive Officer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Compare Gilead Sciences to Competitors

A
AbbVie

AbbVie (NYSE: ABBV) researches and develops pharmaceutical products. The company produces pharmaceutical drugs for specialty therapeutic areas such as immunology, chronic kidney disease, hepatitis C, women's health, oncology, and neuroscience. It also offers treatments for diseases including multiple sclerosis, Parkinson's, and Alzheimer's disease. The company was founded in 2013 and is based in North Chicago, Illinois.

Capital Rx Logo
Capital Rx

Capital Rx is a healthcare technology company. It offers a pharmacy benefits management (PBM) platform that reduces administrative costs, improves patient outcomes, and delivers a superior customer experience. It also offers prescription savings cards. It was founded in 2017 and is based in New York, New York.

H
H&S Tech

H&S Tech is a manufacturer and distributor of disposable packaging and medical products from South Korea and China. It supplies general to custom products for government sectors, retail sectors, and food distribution sectors. The company delivers within the United States. It was founded in 2019 and is based in Anaheim, California.

Cardinal Health Logo
Cardinal Health

Cardinal Health manufactures and distributes medical and laboratory products and is a provider of performance and data solutions for healthcare facilities. It helps pharmacies, hospitals, and ambulatory care sites focus on patient care while reducing costs, improving efficiency and quality, and increasing profitability. Cardinal Health is a link in the healthcare supply chain, providing products from suppliers to medical professionals and healthcare facilities. The company was founded in 1979 and is based in Dublin, Ohio.

T
Theracell Advanced Biotechnology

Theracell Advanced Biotechnology provides personalized and precision medicine, enabling individualized treatment with improved outcome. It offers advanced therapy medicinal products (ATMP), which are comprised of gene therapy, somatic cell therapy, and tissue engineered products. Based on viable cells or tissues, their pharmacological, immunologic or metabolic action should be considered as the principal mode of action. The company's therapeutic portfolio spans the areas of orthopedics, dermatology, nephrology, immuno-oncology, and tissue repair and regeneration. Through strategic partnerships Theracell Advanced Biotechnology participates in the global vision of the realization of personalized medicine tailored to individual patient needs.

McKesson Logo
McKesson

McKesson (NYSE: MCK) is a healthcare services and information technology company that focuses on improving health outcomes for patients. It serves hospitals, physician offices, pharmacies, and pharmaceutical companies. The company was founded in 1833 and is based in Irving, Texas.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.